BACKGROUND AND OBJECTIVES: Chronic rejection leads to kidney allograft failure and develops in many kidney transplant recipients. One cause of chronic rejection, chronic antibody mediated rejection (CAMR), is attributed to alloantibodies. Maintenance immunosuppression including prednisone, mycophenolate mofetil (MMF) and calcineurin inhibitors may limit alloantibody production in some patients, but many maintain or develop alloantibody production, leading to CAMR. Therefore, no efficacious therapy to treat CAMR is presently available to prevent the progression of CAMR to kidney allograft failure. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: We performed a retrospective review of 31 subjects with CAMR, of which 14 received Rituximab and 17 subjects did not. Response to Rituximab was defined as decline or stabilization of serum creatinine for at least one year. Data reviewed included demographic, clinical, allograft, post-transplant, and pathological variables. Pathological variables in the diagnostic allograft biopsy were scored according to Banff criteria. RESULTS: The median survival time (MST) for allografts in the control group was 439 days, and for the Rituximab treated group was 685 days. The Rituximab group was dichotomous with 8 subjects showing a medial survival time of 1180 days, and 6 subjects having a median survival time of 431 days. The MST for the responders was statistically significant from the non-responders and controls. No pathological parameter distinguished any subset of subjects. CONCLUSIONS: These data show that Rituximab followed by standard maintenance immunosuppression shows a therapeutic effect in the treatment of CAMR, which is confined to a subset of treated subjects, not identifiable a priori.
BACKGROUND AND OBJECTIVES: Chronic rejection leads to kidney allograft failure and develops in many kidney transplant recipients. One cause of chronic rejection, chronic antibody mediated rejection (CAMR), is attributed to alloantibodies. Maintenance immunosuppression including prednisone, mycophenolate mofetil (MMF) and calcineurin inhibitors may limit alloantibody production in some patients, but many maintain or develop alloantibody production, leading to CAMR. Therefore, no efficacious therapy to treat CAMR is presently available to prevent the progression of CAMR to kidney allograft failure. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: We performed a retrospective review of 31 subjects with CAMR, of which 14 received Rituximab and 17 subjects did not. Response to Rituximab was defined as decline or stabilization of serum creatinine for at least one year. Data reviewed included demographic, clinical, allograft, post-transplant, and pathological variables. Pathological variables in the diagnostic allograft biopsy were scored according to Banff criteria. RESULTS: The median survival time (MST) for allografts in the control group was 439 days, and for the Rituximab treated group was 685 days. The Rituximab group was dichotomous with 8 subjects showing a medial survival time of 1180 days, and 6 subjects having a median survival time of 431 days. The MST for the responders was statistically significant from the non-responders and controls. No pathological parameter distinguished any subset of subjects. CONCLUSIONS: These data show that Rituximab followed by standard maintenance immunosuppression shows a therapeutic effect in the treatment of CAMR, which is confined to a subset of treated subjects, not identifiable a priori.
Authors: N Suciu-Foca; E Reed; V D D'Agati; E Ho; D J Cohen; A I Benvenisty; R McCabe; J M Brensilver; D W King; M A Hardy Journal: Transplantation Date: 1991-03 Impact factor: 4.939
Authors: L C Racusen; K Solez; R B Colvin; S M Bonsib; M C Castro; T Cavallo; B P Croker; A J Demetris; C B Drachenberg; A B Fogo; P Furness; L W Gaber; I W Gibson; D Glotz; J C Goldberg; J Grande; P F Halloran; H E Hansen; B Hartley; P J Hayry; C M Hill; E O Hoffman; L G Hunsicker; A S Lindblad; Y Yamaguchi Journal: Kidney Int Date: 1999-02 Impact factor: 10.612
Authors: P McLaughlin; A J Grillo-López; B K Link; R Levy; M S Czuczman; M E Williams; M R Heyman; I Bence-Bruckler; C A White; F Cabanillas; V Jain; A D Ho; J Lister; K Wey; D Shen; B K Dallaire Journal: J Clin Oncol Date: 1998-08 Impact factor: 44.544
Authors: Minnie Sarwal; Mei-Sze Chua; Neeraja Kambham; Szu-Chuan Hsieh; Thomas Satterwhite; Marilyn Masek; Oscar Salvatierra Journal: N Engl J Med Date: 2003-07-10 Impact factor: 91.245
Authors: Lorraine C Racusen; Robert B Colvin; Kim Solez; Michael J Mihatsch; Philip F Halloran; Patricia M Campbell; Michael J Cecka; Jean-Pierre Cosyns; Anthony J Demetris; Michael C Fishbein; Agnes Fogo; Peter Furness; Ian W Gibson; Denis Glotz; Pekka Hayry; Lawrence Hunsickern; Michael Kashgarian; Ronald Kerman; Alex J Magil; Robert Montgomery; Kunio Morozumi; Volker Nickeleit; Parmjeet Randhawa; Heinz Regele; Daniel Seron; Surya Seshan; Stale Sund; Kiril Trpkov Journal: Am J Transplant Date: 2003-06 Impact factor: 8.086
Authors: M E Reff; K Carner; K S Chambers; P C Chinn; J E Leonard; R Raab; R A Newman; N Hanna; D R Anderson Journal: Blood Date: 1994-01-15 Impact factor: 22.113
Authors: Kenna R Degner; Nancy A Wilson; Shannon R Reese; Sandesh Parajuli; Fahad Aziz; Neetika Garg; Maha Mohamed; Tripti Singh; Didier A Mandelbrot; Sarah E Panzer; Robert R Redfield; Kristin Van Hyfte; Weixiong Zhong; Luis G Hidalgo; Arjang Djamali Journal: Kidney360 Date: 2020-05-28
Authors: Steven E Lipshultz; Jayanthi J Chandar; Paolo G Rusconi; Alessia Fornoni; Carolyn L Abitbol; George W Burke; Gaston E Zilleruelo; Si M Pham; Elena E Perez; Ruchika Karnik; Juanita A Hunter; Danielle D Dauphin; James D Wilkinson Journal: Clinics (Sao Paulo) Date: 2014 Impact factor: 2.365